Oncolytics Biotech Inc. (ONCY) Stock Forecast
ONCY analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.17 / 5 from 6 analysts
- Price target
- $4.18 average of analyst targets
- Upside to target
- +735.9% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.06
- 52-week range
- $0.47 – $1.27
ONCY analyst ratings
6 analystsNumber of analysts at each rating.
ONCY price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ONCY earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.08 | −$0.08 | −$0.07 | −$0.14 | +43.8% | 3 |
| Current fiscal year (2026) | −$0.38 | −$0.39 | −$0.37 | −$0.42 | +9.2% | 2 |
| Next fiscal year (2027) | −$0.28 | −$0.28 | −$0.23 | −$0.38 | +26.2% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ONCY revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
ONCY EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ONCY EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.08 | −$0.08 | −$0.08 | −$0.08 | −$0.08 | +3.6% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.37 | −$0.37 | −$0.37 | −$0.38 | −$0.38 | +2.1% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.34 | −$0.34 | −$0.34 | −$0.34 | −$0.34 | +0.7% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ONCY earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ONCY beat in 7 of 12.
What analysts expect from ONCY
6 analysts cover Oncolytics Biotech; their consensus rating is buy (4.17 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.18, 735.9% above the latest close of $0.50. Analysts expect earnings of −$0.38 per share for 2026, +9.2% from a year earlier. For 2027 the average estimate is −$0.28 per share. Oncolytics Biotech beat the EPS estimate in 7 of the last 12 quarters.
Related: ONCY income statement, ONCY chart. See the ONCY stock overview for the latest quote and news.
ONCY forecast FAQ
What is Oncolytics Biotech's price target?
The average analyst price target for Oncolytics Biotech is $4.18, 735.9% above the latest close of $0.50.
Is Oncolytics Biotech a buy, hold or sell?
Of 6 analysts covering Oncolytics Biotech, 2 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Oncolytics Biotech's EPS forecast?
Analysts forecast −$0.38 per share for 2026 (range −$0.39 to −$0.37); for 2027 the estimate is −$0.28.
When does Oncolytics Biotech report earnings?
Oncolytics Biotech is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.06.
Does Oncolytics Biotech usually beat earnings estimates?
Oncolytics Biotech reported EPS at or above the analyst estimate in 7 of the last 12 quarters.